Pioneering precision medicines…to one day eliminate cancer as a cause of death. Every cancer is as unique as the person facing it, which is why it is critical to treat the right patient with the right medicine at the right time. We are focused on uncovering the myriad ways that cancer grows and evades detection, with the aim of developing targeted cancer treatments designed to treat those unique characteristics – across multiple tumour types and stages of disease.
By conducting groundbreaking research and collaborating with scientists, academic institutions and like-minded, science-led companies to expand capabilities, Astrazeneca aims to break barriers in how we understand and fight cancer—and one day, eliminate cancer as a cause of death.
Multinational biopharmaceutical company Celgene, world leader in developing new treatments for cancer and inflammatory diseases, established the Celgene Institute for Translational Research Europe (CITRE) in Seville, Spain, in 2010. CITRE is the company’s first dedicated R&D site outside the USA and provides a bridge between Celgene R&D and the European research community.
CITRE houses a team of 25 highly qualified scientific research and administrative staff. Its activities focus on Translational Research into new treatments for cancer and other rare and complex diseases, to ensure that laboratory advances in personalized medicine reach the patients who need them as soon as possible.
Cell Stress Discoveries are an innovative startup focused on developing novel therapeutic solutions for cancer and chemotherapy resistant cancer. The endoplasmic reticulum (ER) is a structure within cells that is responsible for multiple functions, including serving as a sensor of cellular stress. Persistent ER stress has a significant impact in several diseases including cancer and neurodegenerative disease, as well as autoimmune conditions. Extensive research by our academic founders and others has defined a role of the unfolded protein response (UPR) pathway, a major constituent of ER stress, in the survival of tumour cells seen in incidences of chemotherapy resistance. Cell Stress Discoveries was founded with the goal of developing therapeutic candidate molecules that will switch off this tumour survival mechanism.
Genuity Science is a contract genomics and data sourcing, analytics and insights organization headquartered in Boston, Massachusetts, USA with offices in Dublin, Ireland and Reykjavik, Iceland. Genuity partners with global biopharma companies to offer deep end-to-end discovery services aimed at catalyzing precision health and improving the quality of life for patients around the world. Services include population-scale, disease-specific data sourcing, high-quality sequencing, robust statistical analysis and software tools for analyzing large datasets and artificial intelligence (AI). The company operates advanced CAP/CLIA genomics laboratories in Woburn, Massachusetts, USA and in Dublin, Ireland and is deeply committed to data stewardship and data governance across its global offices.
Helsinn, a privately-owned Swiss Pharma Company has, since 1976, been improving the lives of patients all around the world, guided by core family values of respect, integrity and quality. The Group, one of the world’s leading supportive care company, has an extensive portfolio of marketed innovative cancer and rare disease therapies, a robust drug development pipeline and ambitions to further accelerate its growth through strong investment in R&D, in-licensing, and acquisition to address unmet medical needs and to provide new solutions where no options currently exist. Helping to lift the burden of cancer for patients is at the heart of everything Helsinn does.
OncoMark is an Irish diagnostics company focused on the development of novel panels of cancer biomarkers to aid treatment decisions and allow more tailored patient management, ultimately improving the quality of life for cancer patients. Our aim is to develop and commercialise a comprehensive portfolio of proprietary oncological assays that address unmet clinical needs and market gaps. OncoMark’s lead product, OncoMasTR, is a novel prognostic test for early stage breast cancer.
pHion Therapeutics Ltd. is dedicated to precise and efficient drug delivery using targeted nanoparticles. pHion's peptide-based nanoparticle can deliver anionic cargo to specific tissues and cells using a proprietary mechanism of action. By mimicking how viruses target and infect cells throughout the body, whilst being completely non-viral, pHion has created a simple & self-assembling drug delivery system that is easy to use and highly cost effective. pHion's drug delivery technology will ensure that each drug has its maximal therapeutic effect.